UBS Group
ROSG

UBS Group’s Rosetta Genomics Ltd. ROSG Stock Holding History

UBS Group’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,870
Closed -$6K – 8622
2018
Q1 		$6K Buy
14,870
+9,372
+170% +$4.55K ﹤0.01% 7199
2017
Q4 		$3K Buy
5,498
+904
+20% +$709 ﹤0.01% 7579
2017
Q3 		$5K Buy
4,594
+4,469
+3,575% +$7.91K ﹤0.01% 7274
2017
Q2 		$0 Hold
125
– – ﹤0.01% 8404
2017
Q1 		$0 Sell
125
-600
-83% -$3.23K ﹤0.01% 8343
2016
Q4 		$4K Sell
725
-610
-46% -$4.67K ﹤0.01% 7374
2016
Q3 		$13K Sell
1,335
-2,206
-62% -$26.8K ﹤0.01% 6638
2016
Q2 		$49K Buy
3,541
+3,493
+7,277% +$49.8K ﹤0.01% 5542
2016
Q1 		$1K Sell
48
-392
-89% -$5K ﹤0.01% 7527
2015
Q4 		$6K Buy
440
+410
+1,367% +$8.84K ﹤0.01% 7653
2015
Q3 		$1K Buy
+30
New +$1.02K ﹤0.01% 8302
2015
Q1 		– Sell
-271
Closed -$7K – 9826
2014
Q4 		$7K Buy
+271
New +$8.8K ﹤0.01% 8757

Other funds holding ROSG

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS Group's ROSG Position: Q2 2018 in Review

UBS Group sold out of Rosetta Genomics Ltd. (ROSG) in Q2 2018, closing a stake of 14,870 shares — an estimated $6K sold.

UBS Group first reported a position in ROSG in Q4 2014 and held it in 12 quarters. The position peaked at $49K in Q2 2016. 2 funds tracked by Wall St. Rank hold ROSG as of Q2 2018.

  • UBS Group reported no remaining Rosetta Genomics Ltd. position as of Q2 2018 after selling out during the quarter.
  • UBS Group sold 14,870 Rosetta Genomics Ltd. shares in Q2 2018, an estimated $6K.
  • UBS Group first reported a position in Rosetta Genomics Ltd. in Q4 2014 and held it in 12 quarters.
  • UBS Group's Rosetta Genomics Ltd. position peaked at $49K in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2018.

Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.